文献速递甲状腺疾病

甲状腺乳头状癌大体特征与BRAFV600E及TERT启动子突变共存的关联:结合临床病理特征的综合分析

Association Between Gross Features and Coexistence of BRAFV600E and TERT Promoter Mutations in Papillary Thyroid Carcinomas: A Combined Analysis Incorporating Clinicopathologic Features.
PubMed 文献 · Thyroid · 2024-10-31

该回顾性研究分析了2018年1月至2023年10月单中心手术切除的375例甲状腺乳头状癌(PTC),评估大体特征与BRAFV600E及TERT启动子双突变的关系。双突变见于78例(20.8%),与较短的无病生存期(DFS)显著相关。多变量分析显示年龄≥55岁、肿瘤>2.0 cm、分叶状边缘、切面乳头状突起、实性切面、甲状腺外侵犯(ETE)及Ki-67标记指数≥5%与双突变显著相关。

要点

  • BRAFV600E与TERT启动子双突变见于20.8%的PTC病例,与较短DFS显著相关。
  • 年龄≥55岁、肿瘤>2.0 cm、分叶状边缘、切面乳头状突起、实性切面与双突变显著相关。
  • 微小ETE、大体ETE及Ki-67 LI≥5%亦与双突变显著相关。

核心结论

  • PTC中BRAFV600E与TERT启动子双突变与相对高龄、较大肿瘤、分叶状边缘、切面乳头状突起、实性切面、ETE及高Ki-67 LI显著相关,这些特征提示双突变存在,应对PTC患者进行分子水平分析。

研究设计与样本

  • 回顾性分析2018年1月至2023年10月单中心手术切除的375例PTC病例,依据BRAFV600E与TERT启动子双突变状态评估临床病理特征(包括肿瘤切面大体特征),并用Cox比例风险模型分析分子病理特征对无病生存期(DFS)的影响。

主要发现

  • 375例PTC中78例(20.8%)检出BRAFV600E与TERT启动子双突变,双突变与较短DFS显著相关。
  • 多变量分析显示年龄≥55岁(OR=12.083,95%CI 4.498-32.456)、肿瘤>2.0 cm(OR=2.722,95%CI 1.104-6.712)、分叶状肿瘤边缘(OR=16.114,95%CI 3.155-82.296)、切面乳头状突起(OR=17.573,95%CI 3.462-89.201)、实性切面(OR=4.012,95%CI 1.084-14.849)、微小ETE(OR=4.156,95%CI 1.209-14.282)、大体ETE(OR=6.517,95%CI 1.734-24.490)及Ki-67 LI≥5%(OR=12.145,95%CI 4.354-33.877)与双突变显著相关。

临床怎么用

  • 作者认为上述特征提示PTC中可能存在双突变,应对PTC患者进行分子水平分析。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: The coexistence of v-Raf murine sarcoma viral oncogene homolog B1 (BRAFV600E) and telomere reverse transcriptase promoter (TERT-p) mutations is considerably associated with aggressiveness and poor prognosis in papillary thyroid carcinoma (PTC). However, the association between gross findings and genetic alterations in PTC remains unknown. We aimed to investigate the association between clinicopathologic features, including macroscopic features, and the coexistent BRAFV600E and TERT-p mutations in patients with PTC. Methods: We retrospectively analyzed 375 cases of PTC surgically resected between January 2018 and October 2023 at a single institution, based on the presence of BRAFV600E and TERT-p double mutation. Clinicopathologic features, including gross features on the cut surface of tumors, were evaluated. Subsequently, the association between clinicopathologic features and mutation status was statistically examined. Cox proportional hazard models were used to analyze the impact of molecular pathological features on disease-free survival (DFS). Results: The BRAFV600E and TERT-p double mutation was identified in 78 (20.8%) patients among the PTC cases and was significantly correlated with shorter DFS. Multivariable analysis revealed that factors such as relatively older age (≥55 years) (odds ratio [OR] = 12.083, 95% confidence interval [CI] 4.498-32.456), larger tumor size (>2.0 cm) (OR = 2.722, CI 1.104-6.712), lobulated tumor margins (OR = 16.114, CI 3.155-82.296), papillary excrescences on the cut surface (OR = 17.573, CI 3.462-89.201), solid-cut surface (OR = 4.012, CI 1.084-14.849), minimal extrathyroidal extension (ETE) (OR = 4.156, CI 1.209-14.282), gross ETE (OR = 6.517, CI 1.734-24.490), and Ki-67 labeling index (LI) (≥5%, OR = 12.145, CI 4.354-33.877) were significantly associated with the double mutation. Conclusions: The BRAFV600E and TERT-p double mutation in PTC was significantly associated with relatively old age, larger tumor size, lobulated configuration in tumor margin, papillary excrescences on the cut surface, solid-cut surface, ETE, and high Ki-67 LI. These features are suggestive of the presence of the double mutation and should be analyzed at the molecular level in patients with PTC.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Nguyen TNA, Nguyen VPT, Kurohama H, et al. Association Between Gross Features and Coexistence of BRAFV600E and TERT Promoter Mutations in Papillary Thyroid Carcinomas: A Combined Analysis Incorporating Clinicopathologic Features. Thyroid. 2024. PMID: 39479802. doi:10.1089/thy.2024.0310

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。